Rua Expands Global Reach with UK Distribution Agreement
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
FOR PUBLIC RELEASE
NZX Limited
Wellington
14
th
December 2023
Rua Bioscience Expands Global Reach with UK Distribution Agreement
Rua Bioscience is thrilled to announce another milestone in its export strategy with the
signing of a two-year distribution agreement with Target Healthcare, a pharmaceutical
distributor based in the United Kingdom.
This agreement marks a crucial step in Rua Bioscience’s commitment to broadening its
international presence and ensuring the accessibility of its premium medicinal cannabis
products on a global scale. Leveraging the extensive network of Target Healthcare, Rua
Bioscience aims to distribute its products across the United Kingdom, capitalising on this
rapidly growing medicinal cannabis market.
Paul Naske, CEO of Rua Bioscience, commented on this strategic agreement, stating: “This
partnership with Target Healthcare is a significant step in the journey of our company. It
represents a crucial step in establishing our brand and cultivating a robust presence in the
UK medicinal cannabis market.” Mr. Naske further emphasised that this strategic move
initiates a series of regulatory milestones, with anticipated revenues expected in the UK
market by the conclusion of 2024.
Target Healthcare is an ideal distribution partner for Rua Bioscience, focusing specifically on
the niche segment of the pharmaceutical sector where medicinal cannabis holds a
significant position.
Rua Bioscience remains focused on its strategy of establishing distribution channels in key
export markets and distributing our unique Tairawhiti east coast cannabis varieties in these
markets.
About Target Healthcare
Target Healthcare is a prominent pharmaceutical distributor in the United Kingdom,
specialising in the supply and distribution of pharmaceutical and healthcare products,
particularly within the “specials” category, referring to unlicensed medicines.
ENDS
The person who authorised this announcement:
Paul Naske,
Chief Executive Officer
ANNOUNCEMENT
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com
For shareholder enquiries please visit www.ruabio.com or contact:
info@ruabio.com
0800 RUABIO
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- NZL — New Zealand Rural Land Company Limited: FY23 Results Announcement2024-02-28
“29 New Zealand Rural Land Company INDEX INCLUSIONS AND BROKER RESEARCH COVERAGE FTSE Global Micro Cap IndexS&P / NZX All Real Estate Index Broker Research Coverage Nicholas Hill nicholas.hill@craigsip.com Kieran Carling kieran.carling@craigsip.com Arie Dekker arie.dekker@jarden.c…”
- NZL — New Zealand Rural Land Company Limited: Roc Partners Transaction Settlement2024-02-08
“E: info@nzrlc.co.nz | T: +64 9 217 2905 www.nzrlc.co.nz 9 February 2024 Market Update Roc Partners Transaction Settlement NZL is pleased to announce that the agreement to sell a 25% equity interest in its land portfolio to Roc Partners settled today for NZ$44.2m. NZL’s 19 J…”
- AFT — AFT Pharmaceuticals Limited: NEW YEAR LETTER TO INVESTORS2024-01-08
“AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com These agreements have also seen a strengthening of our relationships with long term partners…”